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Background: Increased apoptosis may induce autoimmune conditions. Apoptosis is induced by binding of
death receptor ligands, members of the tumour necrosis factor (TNF) superfamily, to their cognate
receptors. The Fas–Fas ligand pathway has been studied extensively in relation to systemic lupus
erythematosus (SLE). However, other death pathways are also considered important. TNF related
apoptosis inducing ligand (TRAIL), another ligand of the TNF superfamily, induces apoptosis in sensitive
cells.
Objective: To assess soluble (s) TRAIL concentrations in sera of SLE patients.
Methods: 40 SLE patients were studied (20 with active and 20 with inactive disease). Serum sTRAIL
concentrations were measured by a solid phase sandwich enzyme linked immunosorbent assay. Levels in
SLE patients were compared with those in patients with rheumatoid arthritis (n = 20), Wegener’s
granulomatosis (n = 20), and healthy controls (n = 20).
Results:Mean (SEM) serum sTRAIL concentration in SLE patients (936.0 (108.2) pg/ml) was higher than in
healthy controls (509.4 (33.8) pg/ml; p,0.01) or in disease control patients with rheumatoid arthritis
(443.8 (36.1) pg/ml, p,0.001) or Wegener’s granulomatosis (357.1 (32.2) pg/ml; p,0.001). The
mean serum sTRAIL concentration was 1010.2 (168.0) pg/ml for patients with inactive disease and 861.8
(138.7) pg/ml for those with active disease. sTRAIL values were not correlated with specific manifestations
of the disease, such as leucopenia or lymphopenia, or with SLE disease activity index.
Conclusions: Serum sTRAIL concentrations are increased SLE patients. This seems to be disease specific
and could indicate a role for TRAIL in SLE pathophysiology.
S
ystemic lupus erythematosus (SLE) is an autoimmune
disease with a broad spectrum of clinical and immuno-
logical abnormalities. The presence of autoantibodies,
especially those directed to double stranded DNA, is
characteristic of the disease. SLE may affect different organ
systems, including the skin, joints, central and peripheral
nervous system, kidneys, and liver. The aetiology of the
disease remains unknown. There is, however, increasing
evidence that the presence and accumulation of apoptotic
cells play a role in autoimmunity.1
Apoptosis (programmed cell death) is an active physiolo-
gical process that leads to the ordered destruction of cells
without the release of intracellular contents into the
extracellular environment (which would cause an inflam-
matory reaction and tissue damage). It is fundamental to
maturation and homeostasis of the immune system.
Apoptosis can be induced passively, through lack of essential
survival signals, or actively, through ligand induced trimer-
isation of specific death receptors of the tumour necrosis
factor (TNF) receptor family, such as Fas, the TNF receptor,
or the TNF related apoptosis inducing ligand (TRAIL)
receptor.
The Fas mediated apoptosis pathway has been studied
extensively in relation to SLE and other autoimmune diseases
(reviewed by Nagata2 and Famularo et al3). Fas, also known
as APO-1 or CD95, is an apoptosis signalling receptor on the
cell surface. It is expressed on subpopulations of peripheral
blood lymphocytes, predominantly memory T cells, and upon
activation it is strongly upregulated on both T and
B lymphocytes. It can also be found in serum as a soluble
form, lacking its transmembrane region. Soluble Fas (sFas) is
functionally active when injected into female CD1 mice,
resulting in autoimmune features and lymphadenopathy4; in
that study it was shown that sFas blocked Fas induced
apoptosis. Serum sFas and soluble Fas ligand (sFasL) levels
are raised in patients with SLE.5 However, in contrast to the
data obtained from animal models, in SLE patients the
induction of Fas induced apoptosis in peripheral blood
lymphocytes is increased rather than decreased.
TRAIL (APO-2 ligand) is a transmembrane (type II)
glycoprotein which also belongs to the TNF superfamily.6
The extracellular domain of TRAIL is homologous to that of
other family members and shows a homotrimeric subunit
structure. Like TNF and FasL, TRAIL also exists physiologi-
cally in a biologically active soluble homotrimeric form.
TRAIL triggers apoptosis through interaction with the death
receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (reviewed by
LeBlanc and Ashkenazi7).
There are several indications that TRAIL could be involved
in the pathophysiology of autoimmune diseases in general
and SLE in particular. In patients with multiple sclerosis,
FasL and TRAIL are upregulated in peripheral blood mono-
nuclear cells.8 In patients with Sjögren’s syndrome TRAIL-R1
and TRAIL-R2 are strongly expressed on the ductal epithelial
cells in the salivary glands.9 Recently Kaplan et al reported
that increased expression of TRAIL and FasL found on
activated T cells contributes to increased monocyte apoptosis
in patients with SLE.10 Furthermore increased mRNA for
TRAIL and its decoy receptors (TRAIL-R3 and TRAIL-R4) was
found in peripheral blood mononuclear cells from SLE
patients.11
Abbreviations: ACR, American College of Rheumatology; ELISA,
enzyme linked immunosorbent assay; FasL, Fas ligand; IFN, interferon;
OD, optical density; PBMC, peripheral blood mononuclear cells; SLE,
systemic lupus erythematosus; SLEDAI, SLE disease activity index; TNF,



















The Fas/FasL system in SLE is functionally intact, but
upregulation of these membrane molecules does not seem to
explain the increased numbers of apoptotic cells found in the
peripheral blood of these patients.12 We hypothesise that
secreted sTRAIL might also be important in the induction of
apoptosis in SLE. Currently there are no data on serum
sTRAIL concentrations in SLE patients compared with
healthy volunteers and disease controls with rheumatoid
arthritis or Wegener’s granulomatosis. Matsuyama et al
recently showed that serum TRAIL concentrations were
negatively correlated with neutrophil counts in SLE patients,
suggesting that there is sTRAIL induced apoptosis of
neutrophils in SLE.13 It is, however, unknown whether
increased sTRAIL levels in SLE patients are disease specific
and dependent on disease activity.
METHODS
Patients
Clinical data and serum samples for all patients with SLE
who are referred to the University Hospital Groningen are
stored consecutively in a computerised database. The patients
for our study were selected from this database. They were
eligible for the study if they fulfilled at least four American
College of Rheumatology (ACR) criteria for SLE.14 We
included 20 consecutive SLE patients with inactive disease,
defined as the persistent absence of disease activity (SLE
disease activity index (SLEDAI) (4) over at least a four
month period with no immunomodulating drug treatment or
on a constant dose of an immunomodulating agent. The
SLEDAI score was calculated for each patient.15 In addition,
the effect of disease activity in 20 SLE patients with active
disease was studied. Patients with active disease had to fulfil
previously defined criteria.16 As disease controls we included
consecutive patients with rheumatoid arthritis (n=20; 5
male, 15 female; mean (SD) age, 51.5 (12.1) years) and
Wegener’s granulomatosis (n=20; 13 male, 7 female; 51.2
(21.1) years), all fulfilling respective ACR criteria.17 18.
Healthy volunteers (n=20; 9 male, 11 female; 37.4 (11.5)
years) served as controls.
Laboratory assessments
For SLE patients laboratory assessments included serum
levels of C3, C4, and C reactive protein, and leucocyte,
neutrophil, monocyte, and lymphocyte counts. Antibodies to
dsDNA were detected by Farr assay.
Enzyme linked immunosorbent assay for TRAIL
Serum samples were stored at 220 C̊ until assayed for
sTRAIL concentrations. Serum levels of sTRAIL were deter-
mined by a validated sandwich solid phase enzyme linked
immunosorbent assay (ELISA) (Diaclone, Besançon, France).
A monoclonal antibody specific for sTRAIL was coated onto
the wells of the microtitre strips. An aliquot of 100 ml of
undiluted serum was pipetted in duplicate into the wells.
During the first incubation, the sTRAIL antigen and a
biotinylated monoclonal antibody specific for sTRAIL were
simultaneously incubated for three hours at room tempera-
ture (18–25 C̊). After washing, the enzyme streptavidin-poly
horseradish peroxidase was added. After incubation for 30
minutes and washing to remove unbound enzyme, a
substrate solution was added to the bound enzyme to induce
a coloured reaction product. The optical density (OD),
reflecting the intensity of the product, was measured in a
spectrophotometer using 450 nm as the primary wavelength
and 650 nm as the reference wavelength. Linear calibration
curves were made using standard TRAIL (0–3000 pg/ml),
provided with the kit. The amount of sTRAIL in the serum
samples was determined by extrapolating OD values to TRAIL
concentrations using the calibration curves. The minimum
detectable dose was 64 pg/ml. Intra-assay and interassay
variation was 5.5–7.4% and 3.8–8.0%, respectively. The ELISA
was found to be specific for TRAIL; cross reactivity with TNFa
was absent and the signal could be blocked specifically by the
addition of soluble TRAIL receptors.
Statistical analysis
Data are presented as mean (SEM). Differences in mean
sTRAIL levels between the patient groups and normal
controls were determined by ANOVA and Bonferroni post
hoc test (Gaussian distribution) and by the x2 test. The
Table 1 Characteristics of patients with systemic lupus erythematosus
Variable Active (n = 20) Inactive (n = 20) p Value
Age (years) (mean (range)) 40.3 (19 to 77) 41.0 (23 to 72) .0.05
Male/female 4/16 3/17
Anti-dsDNA by Farr (IU/ml) 162.6 (57.6) 15.35 (3.4) 0.015
C3 (g/l) 0.757 (0.080) 0.982 (0.060) 0.032
C4 (g/l) 0.105 (0.010) 0.148 (0.010) 0.047
SLEDAI 9.950 (1.065) 1.950 (0.387) ,0.0001
CRP (mg/l) 35.45 (10.68) 3.45 (1.06) 0.0005
Creatinine (mmol/l) 91.60 (8.54) 96.00 (7.54) 0.70
Leucocytes (6109/l) 4.42 (0.50) 5.40 (0.50) 0.15
Neutrophils (6109/l) 3.24 (0.58) 3.78 (0.41) 0.44
Monocytes (6109/l) 0.28 (0.05) 0.45 (0.05) 0.016
Lymphocytes (6109/l) 0.81 (0.14) 1.04 (0.16) 0.29
sTRAIL (pg/ml) 861.8 (138.7) 1010.0 (168.0) 0.50
Renal disease 6 –
Central nervous system disease 3 –
Serositis 4 –
Haematological disease 7 –
Polyarthritis 6 –
Skin involvement 4 –
Fever 5 –
No immunosuppressive drugs 11 6
Prednisolone (2.5 to 10 mg) 3 8
Azathioprine (50 to 150 mg) – 1
Prednisolone + azathioprine 6 5
Values are mean (SEM) or n, unless stated.
Significant p values in bold.
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Spearman test was used to determine correlations. Student’s
t test was used to determine differences between sTRAIL
levels in men and women (control group). A probability (p)
value of ,0.05 was considered significant.
RESULTS
Characteristics of the SLE patients are given in table 1.
Patients with rheumatoid arthritis had a mean (SEM) C
reactive protein concentration of 10.5 (2.1) mg/l, a mean
serum creatinine of 79.9 (2.5) mmol/l, and a mean leucocyte
count of 6.9 (0.3)6109/l. Patients with Wegener’s granulo-
matosis had a mean C reactive protein concentration of 7.3
(1.7) mg/l, a mean serum creatinine of 109.5 (7.9) mmol/l,
and a mean leucocyte count of 7.8 (0.9)6109/l.
To evaluate whether sTRAIL levels are influenced by sex or
age, or both, we determined the correlation between sTRAIL
level and age, and we analysed the difference in sTRAIL
values between men and women in the control group. There
was no difference in mean sTRAIL concentration between
men (n=9; 557.7 (39.2) pg/ml) and women (n=11; 469.9
(50.8) pg/ml) (p=0.2). There was also no correlation
between age and sTRAIL concentration (p=0.31, r=20.24).
The mean (SEM) serum sTRAIL concentration was 1010.2
(168.0) pg/ml for patients with inactive disease and 861.8
(138.7) pg/ml for those with active disease. The difference
between the two groups was not significant (p.0.05).
Eighty three per cent of the SLE patients (33 of 40) had a
mean sTRAIL level above that of the healthy volunteers, at
509 (33.8) pg/ml. Of the 20 patients with inactive disease one
had a serum level below the mean control value. In patients
with active disease this was seen in six of the 20 patients
(p=0.037, x2 test).
The serum sTRAIL concentration in the whole group of SLE
patients was 936.0 (108.2) pg/ml. Values were 443.8 (36.1)
pg/ml in patients with rheumatoid arthritis and 357.1 (32.2)
pg/ml in those with Wegener’s granulomatosis. Serum
sTRAIL concentrations in SLE patients were higher than
those in healthy volunteers or disease control patients with
rheumatoid arthritis or Wegener’s granulomatosis (p,0.05;
fig 1). Serum sTRAIL concentrations in rheumatoid arthritis
did not differ from those in the healthy volunteers or
the patients with Wegener’s granulomatosis (p.0.05).
Concentrations in Wegener’s granulomatosis did not differ
from those in the healthy volunteers (p.0.05).
We examined the association between the level of serum
sTRAIL and specific clinical features (fig 2). No clear relation
was found between serum sTRAIL concentration and renal,
cerebral, cutaneous, serosal, haematological, or musculoske-
letal disease manifestations. Patients with serositis seemed to
have lower serum sTRAIL levels, although numbers were
small. Furthermore there was no correlation between the
SLEDAI score and serological indices of disease activity such
as anti-dsDNA and complement C4 levels, and no correlation
with C reactive protein levels. However, there was a positive
correlation between serum sTRAIL level and complement C3
(p=0.02).
Leucopenia is seen in patients with active SLE. As sTRAIL
can induce apoptosis in lymphocytes, monocytes, and
neutrophils, we analysed whether sTRAIL levels were
correlated with blood cell counts. Analysing all patients, no
correlation was found between serum sTRAIL concentration
and monocyte, lymphocyte, or leucocyte counts. However,
when we focused on six patients with neutropenia
(,1.56109 neutrophils/l; three with active and three with
inactive SLE) we found that the serum sTRAIL concentra-
tions in these patients tended to be higher than in SLE
patients without neutropenia, at 1455 (626) v 853.6 (66.7) pg/
ml (p=0.057).
Finally, we examined the relation between sTRAIL
concentrations and immunosuppressive drug treatment
(prednisolone and azathioprine). No correlation between
the use of these agents and sTRAIL values was found (data
not shown).
DISCUSSION
Increased neutrophil, monocyte, and lymphocyte apoptosis is
a characteristic feature of SLE pathophysiology.19 Thus the
role of the apoptosis inducing ligands of the TNF family and
their death receptors has been explored for years. The Fas/
FasL system contributes to increased apoptosis. The impor-
tance of the other death pathways is, however, uncertain.
Recent interest had focused on TRAIL, several studies
indicating that it is involved in the pathophysiology of
























Figure 1 Serum soluble TNF related apoptosis inducing ligand (sTRAIL)
concentrations (pg/ml) in SLE patients with inactive disease (n =20), SLE
patients with active disease (n = 20), disease control patients with
rheumatoid arthritis (n = 20), disease control patients with Wegener’s
granulomatosis (n = 20), and healthy controls (n = 20). The horizontal







































Figure 2 Serum soluble TNF related apoptosis inducing ligand (sTRAIL)
concentrations (pg/ml) in patients with systemic lupus erythematosus
(SLE) who had active disease (n = 20) divided by clinical disease
manifestation (n = 35). One patient could have different manifestations of
SLE; thus 35 disease manifestations were found in 20 patients. The
horizontal lines give the mean sTRAIL value.
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The present study showed higher sTRAIL concentrations in
the serum of SLE patients compared with healthy volunteers
and patients with rheumatoid arthritis or Wegener’s granu-
lomatosis. This suggests that increased serum sTRAIL levels
are disease specific for SLE.
Through interaction with its death receptors TRAIL-R1 and
TRAIL-R2, increased sTRAIL concentrations can stimulate
increased apoptosis of lymphocytes and monocytes and may
have a pathophysiological role in SLE, as increased apoptosis
can result in the accumulation of apoptotic cells. Accumula-
tion of apoptotic cells might induce autoimmunity.20
A question remains about the origin of the increased serum
sTRAIL levels in SLE patients. Peripheral blood lymphocytes
are activated in SLE patients even during clinically inactive
disease.21 T cell activation has been found to contribute to
increased expression of TRAIL and other apoptotic ligands on
lupus T cells isolated from SLE patients.10 In vitro, further-
more, TRAIL could be released from activated T cells22 as well
as from stimulated monocytes.23 These findings are supported
by increased gene expression of TRAIL and its decoy receptors
in peripheral blood mononuclear cells (PBMC) from SLE
patients.11 This overexpression could result in increased
TRAIL concentrations.
Interferons (IFNa, b, and c) might also play an important
role. Overexpression of IFN induced genes occurs in PBMC of
paediatric SLE patients.24 This is of interest as human
monocytes rapidly express TRAIL following activation with
IFNa and IFNc.25 26 Furthermore in breast cancer cell lines,
using DNA microarrays to profile TRAIL-mediated gene
expression, interaction between TRAIL death signalling and
IFN pathways (including interferon b and c) is suggested.27
Increased concentrations of sTRAIL may be explained by
immunosuppressive drugs, which are known to induce
apoptosis. This could subsequently lead to sTRAIL release
from apoptotic cell fragments. For this reason we examined
the relation between sTRAIL concentrations and the use of
immunosuppressive drugs (prednisolone and azathioprine).
We did not find a clear correlation in this small patient
population, which excludes a substantial influence of drugs.
It was of interest that serum sTRAIL concentrations in
patients with quiescent disease were more often increased
than in patients with active disease. As TRAIL has an
extremely short calculated half life of only 30 minutes28 this
indicates continuous TRAIL production or secretion.
Furthermore, as 30% of the patients with active disease had
a level below the mean serum sTRAIL, we conclude that
serum sTRAIL levels tend to decrease during, or perhaps prior
to, active disease. This could be interpreted as binding of
TRAIL to its receptors, distribution of sTRAIL throughout the
body, or decreased TRAIL production. Binding of sTRAIL to
its death receptors could lead to increased apoptosis of
monocytes and lymphocytes. This is supported by the
decreased monocyte and lymphocyte counts found in
patients with active SLE (table 1). We were, however, unable
to find a correlation between serum sTRAIL levels and blood
cell counts in patients with SLE.
Recently Matsuyama et al13 showed that serum TRAIL
values correlated negatively with neutrophil counts in SLE
patients, suggesting that there is sTRAIL induced apoptosis of
neutrophils in SLE. Our data are largely in accord with
Matsuyama’s data. Probably because of the small number of
patients with neutropenia in our study (only six), the relation
we found did not reach significance. The serum sTRAIL
values in the patients with neutropenia, however, tended to
be higher than in the patients without neutropenia
(p=0.057).
The correlation between sTRAIL level and complement C3
is unexpected and unexplained. We cannot exclude the
possibility that correlations were not demonstrated owing to
the relatively small number of patients with a very hetero-
geneous disease.
Recently it was shown that TRAIL is important in the
prevention of autoimmune diseases in experimental animal
models.29–31 Blocking TRAIL with soluble TRAIL receptor
exacerbated autoimmune encephalomyelitis29 and enhanced
proliferation of autoreactive lymphocytes or synovial cells.30
Furthermore, TRAIL deficient C57BL/6 mice have an
increased susceptibility to autoimmune diseases.31 Our results
in SLE patients contrast with animal data but do not exclude
an important function of sTRAIL in these patients. A
prospective longitudinal study is needed to investigate serum
sTRAIL values over time with respect to disease activity and
immunosuppressive treatment. Investigation of TRAIL and
TRAIL-R expression and function in tissues, and on mono-
cytes and lymphocytes, in SLE patients is also eagerly
awaited.
Conclusions
In this study we report that increased serum sTRAIL
concentrations in SLE patients seems to be disease specific.
Levels in patients with inactive disease are more often
increased than in patients with active disease. These findings
could indicate an important role for sTRAIL in the pathogen-
esis of SLE. However, the exact mechanism and significance
of this remain to be elucidated in larger prospective studies.
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